Longitudinal Assessment of SARS-CoV-2 Antinucleocapsid and Antispike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection
| Autor: | Thomas J S Durant, Wade L. Schulz, Joe M. El-Khoury |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 030106 microbiology nucleocapsid Antibodies Viral Polymerase Chain Reaction Diagnostic aid Serology 03 medical and health sciences COVID-19 Testing Predictive Value of Tests In vivo antibody Humans Medicine Longitudinal Studies biology SARS-CoV-2 business.industry COVID-19 spike General Medicine AcademicSubjects/SCI01290 sensitivity Focused Report Virology United States Europe 030104 developmental biology Predictive value of tests Spike Glycoprotein Coronavirus Cohort biology.protein AcademicSubjects/MED00530 AcademicSubjects/SCI00980 Reagent Kits Diagnostic Antibody business AcademicSubjects/MED00690 |
| Zdroj: | The Journal of Applied Laboratory Medicine |
| ISSN: | 2475-7241 2576-9456 |
| Popis: | BackgroundSARS-CoV-2 serologic assays are becoming increasingly available and may serve as a diagnostic aid in a multitude of settings relating to past infection status. However, there is limited literature detailing the longitudinal performance of EUA-cleared serologic assays in US populations, particularly in cohorts with a remote history of PCR-confirmed SARS-CoV-2 infection (e.g., >2 months).MethodsWe evaluated the diagnostic sensitivities and specificities of the Elecsys® Anti-SARS-CoV-2 (anti-N) and Elecsys Anti-SARS-CoV-2 S (anti-S1-RBD) assays, using 174 residual clinical samples up to 267 days post-PCR diagnosis of SARS-CoV-2 infection (n = 154) and a subset of samples obtained prior to the COVID-19 pandemic as negative controls (n = 20).ResultsThe calculated diagnostic sensitivities for the anti-N and anti-S1-RBD assays were 89% and 93%, respectively. Of the 154 samples in the SARS-CoV-2-positive cohort, there were 6 discrepant results between the anti-N and anti-S1-RBD assays, 5 of which were specimens collected ≥200 days post-PCR positivity and only had detectable levels of anti-S1-RBD antibodies. When only considering specimens collected ≥100 days post-PCR positivity (n = 41), the sensitivities for the anti-N and anti-S1-RBD assays were 85% and 98%, respectively.ConclusionsThe anti-S1-RBD assay demonstrated superior sensitivity at time points more remote to the PCR detection date, with 6 more specimens from the SARS-CoV-2-positive cohort detected, 5 of which were collected more than 200 days post-PCR positivity. While analytical differences and reagent lot-to-lot variability are possible, this may indicate that, in some instances, anti-S1-RBD antibodies may persist longer in vivo and may be a better target for detecting remote SARS-CoV-2 infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|